Early Radiation-Induced Sarcoma in an Adolescent Treated for Relapsed Hodgkin Lymphoma with Nivolumab

Overview

Journal Medicina (Kaunas)

Publisher MDPI

Specialty General Medicine

Date 2020 Apr 5

PMID 32244416

Authors

Lukas Salasevicius

Goda Elizabeta Vaitkeviciene

Ramune Pasauliene

Rosita Kiudeliene

Ernesta Ivanauskaite-Didziokiene

Donatas Vajauskas

Nemira Jurkiene

Jelena Rascon

Affiliations

Soon will be listed here.

Abstract

Radiation-induced sarcoma (RIS) has been reported as a late secondary malignancy following radiotherapy for various types of cancer with a median latency of 10 years. We describe an early RIS that developed in an adolescent within three years of treatment (including PD-L1 check-point inhibitor Nivolumab) of a relapsed classic Hodgkin lymphoma (HL) and was diagnosed post-mortem. The patient died of the progressive RIS that was misleadingly assumed to be a resistant HL based on the positive PET/CT scan. Repetitive tumor biopsies are warranted in cases of aggressive and multi-drug resistant HL to validate imaging findings, ensure correct diagnosis and avoid overtreatment.

References

Altaf S, Enders F, Jeavons E, Krailo M, Barkauskas D, Meyers P . High-BMI at diagnosis is associated with inferior survival in patients with osteosarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2013; 60(12):2042-6. DOI: 10.1002/pbc.24580. View

Hodgson D, Gilbert E, Dores G, Schonfeld S, Lynch C, Storm H . Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol. 2007; 25(12):1489-97. DOI: 10.1200/JCO.2006.09.0936. View

Kasamon Y, De Claro R, Wang Y, Shen Y, Farrell A, Pazdur R . FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma. Oncologist. 2017; 22(5):585-591. PMC: 5423515. DOI: 10.1634/theoncologist.2017-0004. View

Walden M, Murphey M, Vidal J . Incidental enchondromas of the knee. AJR Am J Roentgenol. 2008; 190(6):1611-5. DOI: 10.2214/AJR.07.2796. View

Sklar C, Whitton J, Mertens A, Stovall M, Green D, Marina N . Abnormalities of the thyroid in survivors of Hodgkin's disease: data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2000; 85(9):3227-32. DOI: 10.1210/jcem.85.9.6808. View

Strongman H, Brown A, Smeeth L, Bhaskaran K . Body mass index and Hodgkin's lymphoma: UK population-based cohort study of 5.8 million individuals. Br J Cancer. 2019; 120(7):768-770. PMC: 6461799. DOI: 10.1038/s41416-019-0401-1. View

Wolden S, Lamborn K, Cleary S, Tate D, Donaldson S . Second cancers following pediatric Hodgkin's disease. J Clin Oncol. 1998; 16(2):536-44. DOI: 10.1200/JCO.1998.16.2.536. View

Li Q, Chang E, Bassig B, Dai M, Qin Q, Gao Y . Body size and risk of Hodgkin's lymphoma by age and gender: a population-based case-control study in Connecticut and Massachusetts. Cancer Causes Control. 2012; 24(2):287-95. PMC: 3557669. DOI: 10.1007/s10552-012-0100-1. View

Costelloe C, Chuang H, Madewell J . FDG PET/CT of primary bone tumors. AJR Am J Roentgenol. 2014; 202(6):W521-31. DOI: 10.2214/AJR.13.11833. View

10.

Moke D, Hamilton A, Chehab L, Deapen D, Freyer D . Obesity and Risk for Second Malignant Neoplasms in Childhood Cancer Survivors: A Case-Control Study Utilizing the California Cancer Registry. Cancer Epidemiol Biomarkers Prev. 2019; 28(10):1612-1620. PMC: 6774883. DOI: 10.1158/1055-9965.EPI-19-0466. View

11.

Mauz-Korholz C, Metzger M, Kelly K, Schwartz C, Castellanos M, Dieckmann K . Pediatric Hodgkin Lymphoma. J Clin Oncol. 2015; 33(27):2975-85. DOI: 10.1200/JCO.2014.59.4853. View

12.

Stomp W, Reijnierse M, Kloppenburg M, de Mutsert R, Bovee J, den Heijer M . Prevalence of cartilaginous tumours as an incidental finding on MRI of the knee. Eur Radiol. 2015; 25(12):3480-7. PMC: 4636526. DOI: 10.1007/s00330-015-3764-6. View

13.

Buchta C, Boi S, Miller B, Milhem M, Norian L . Obesity Does Not Exacerbate the Protumorigenic Systemic Environment in Sarcoma Subjects. Immunohorizons. 2017; 1(4):20-28. PMC: 5711445. DOI: 10.4049/immunohorizons.1700001. View

14.

Gladdy R, Qin L, Moraco N, Edgar M, Antonescu C, Alektiar K . Do radiation-associated soft tissue sarcomas have the same prognosis as sporadic soft tissue sarcomas?. J Clin Oncol. 2010; 28(12):2064-9. PMC: 3651600. DOI: 10.1200/JCO.2009.25.1728. View

15.

Ng A, Mauch P . Late effects of Hodgkin's disease and its treatment. Cancer J. 2009; 15(2):164-8. DOI: 10.1097/PPO.0b013e31819e30d7. View

16.

Dorffel W, Riepenhausen M, Luders H, Bramswig J . Late Effects Following Treatment of Hodgkin Lymphoma During Childhood and Adolescence. Results of the Hodgkin Lymphoma Late Effects Research Project. Klin Padiatr. 2016; 228(6-07):286-293. DOI: 10.1055/s-0042-110406. View

17.

Sheng X, Mittelman S . The role of adipose tissue and obesity in causing treatment resistance of acute lymphoblastic leukemia. Front Pediatr. 2014; 2:53. PMC: 4046266. DOI: 10.3389/fped.2014.00053. View

18.

Isik E, Kuyumcu S, Kebudi R, Sanli Y, Karakas Z, Cakir F . Prediction of outcome in pediatric Hodgkin lymphoma based on interpretation of FDG-PET/CT according to ΔSUV, Deauville 5-point scale and IHP criteria. Ann Nucl Med. 2017; 31(9):660-668. DOI: 10.1007/s12149-017-1196-x. View

19.

Sirohi B, Cunningham D, Powles R, Murphy F, Arkenau T, Norman A . Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma. Ann Oncol. 2008; 19(7):1312-1319. DOI: 10.1093/annonc/mdn052. View

20.

Dobert N, Menzel C, Ludwig R, Berner U, Diehl M, Hamscho N . Enchondroma: a benign osseous lesion with high F-18 FDG uptake. Clin Nucl Med. 2002; 27(10):695-7. DOI: 10.1097/01.RLU.0000027743.04696.0D. View